The PI3K/AKT/PTEN Pathway as a Therapeutic Target in HR+ Breast Cancer

The PI3K/AKT/mTOR signalling axis is one of the most frequently activated oncogenic pathways in hormone receptor-positive, HER2-negative breast cancer, with activating alterations in PIK3CA, AKT1, or loss of PTEN collectively affecting a substantial proportion of patients who progress on CDK4/6 inhibitor-based therapy. These genomic events converge on AKT — a serine/threonine kinase that acts as a central node integrating upstream growth factor signals into downstream proliferative, survival, and metabolic outputs — making it a logical target for pharmacological intervention in this biomarker-defined population.

Endocrine therapy resistance in HR+/HER2- breast cancer is a well-characterised clinical problem. CDK4/6 inhibitors combined with aromatase inhibitors or fulvestrant have extended progression-free survival in the first-line and second-line settings, but acquired resistance — often accompanied by PI3K/AKT pathway activation — creates a population with limited subsequent options. According to data reported by The New England Journal of Medicine, identifying genomically defined subpopulations for targeted therapy after CDK4/6 inhibitor progression represents one of the most active areas of clinical investigation in breast oncology.

The therapeutic logic for targeting AKT in this context is reinforced by the convergent biology: PIK3CA mutations increase phosphatidylinositol-3,4,5-trisphosphate (PIP3) production, directly activating AKT; AKT1 mutations constitutively activate the kinase itself; and PTEN loss removes the primary phosphatase that degrades PIP3, again driving AKT hyperactivation. Each of these alterations leads to the same downstream effector state, which is why pan-AKT inhibition — blocking all three isoforms — is a mechanistically coherent strategy across this composite biomarker population, as noted in pathway analyses published by Nature.

Capivasertib (AZD5363): Mechanism, Selectivity, and Molecular Rationale

Capivasertib (AZD5363) is a pan-AKT kinase inhibitor developed by AstraZeneca that inhibits all three AKT isoforms — AKT1, AKT2, and AKT3 — by binding to the ATP-binding site of the kinase domain. This isoform-spanning inhibition is a deliberate design choice: because the three biomarker alterations that define the target population (PIK3CA mutation, AKT1 mutation, PTEN loss) can each drive AKT signalling through partially distinct isoform dependencies, a pan-inhibitor provides broader pathway suppression than an isoform-selective agent would in this composite biomarker context.

The mechanistic rationale for combining capivasertib with endocrine therapy such as fulvestrant is grounded in the biology of endocrine resistance. PI3K/AKT pathway activation is a recognised driver of oestrogen receptor (ER)-independent proliferation, enabling tumour cells to bypass the growth-suppressive effects of oestrogen deprivation or ER antagonism. By co-inhibiting AKT and the ER axis simultaneously, the combination aims to close this resistance escape route — a strategy supported by preclinical data reviewed by the National Cancer Institute in the context of endocrine resistance mechanisms.

“By co-inhibiting AKT and the oestrogen receptor axis simultaneously, the capivasertib–fulvestrant combination aims to close the resistance escape route that PI3K/AKT pathway activation provides to endocrine-resistant tumour cells.”

Capivasertib’s molecular profile distinguishes it from earlier PI3K inhibitors such as alpelisib, which targets only the PI3Kα isoform encoded by PIK3CA and therefore has activity primarily in PIK3CA-mutant tumours. By acting downstream at AKT, capivasertib can theoretically address pathway activation arising from any of the three upstream alterations — including AKT1 mutations and PTEN loss — that would not be directly targeted by a PI3Kα-selective inhibitor. This broader biomarker coverage is a central element of the CAPItello programme’s patient selection strategy.

The CAPItello-291 Phase III Programme: Design and Biomarker Strategy

CAPItello-291 is a Phase III clinical trial evaluating capivasertib in combination with fulvestrant in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who carry activating alterations in the PI3K/AKT/PTEN pathway. The trial’s biomarker-selection strategy — enrolling patients with tumours harbouring PIK3CA, AKT1, or PTEN alterations as the primary efficacy population — reflects the mechanistic rationale for pan-AKT inhibition and represents a molecularly stratified approach to clinical trial design.

The trial’s design reflects lessons from the alpelisib (BYLieve, SOLAR-1) programme, which demonstrated that biomarker-selected populations — specifically PIK3CA-mutant tumours — benefit more substantially from PI3K pathway inhibition than unselected populations. CAPItello-291 extends this logic by broadening the biomarker definition to include all three major pathway alterations, a design choice enabled by capivasertib’s pan-AKT mechanism. The combination with fulvestrant as the endocrine backbone aligns with the clinical context of post-CDK4/6 inhibitor progression, where fulvestrant is an established standard of care for ER+/HER2- disease.

The CAPItello-291 programme established capivasertib plus fulvestrant as a clinically active combination in this biomarker-selected population, providing the clinical proof-of-concept that underpins the broader CAPItello expansion programme. Regulatory and scientific interest in the trial’s outcomes reflects the unmet need in post-CDK4/6 inhibitor HR+/HER2- breast cancer, a setting tracked closely by organisations including ASCO and the European Society for Medical Oncology.

CAPItello Expansion: Combination Strategies and Emerging Disease Settings

Following the CAPItello-291 Phase III results, the CAPItello framework is being expanded across different disease settings and therapeutic combinations, exploring capivasertib’s activity beyond the original fulvestrant backbone. This expansion reflects a broader strategic interest in AKT inhibition as a combinatorial partner — both with endocrine agents and with other targeted therapies — in PIK3CA/AKT/PTEN-altered breast cancer and potentially in other solid tumour types where this pathway is activated.

The rationale for combination expansion is mechanistically grounded. AKT inhibition can create synthetic lethality or additive suppression when paired with agents that block parallel survival pathways. In the HR+ breast cancer context, combinations under investigation in the broader CAPItello programme include pairing capivasertib with CDK4/6 inhibitors (to address acquired resistance mechanisms), with mTOR inhibitors (to achieve more complete pathway suppression), and with other endocrine agents beyond fulvestrant. Each combination hypothesis is driven by the biology of PI3K/AKT pathway crosstalk with the relevant co-target.

Disease setting expansion is equally significant. While CAPItello-291 focused on advanced or metastatic HR+/HER2- breast cancer, the CAPItello programme is generating interest in earlier-stage settings — including the neoadjuvant and adjuvant contexts — where PI3K/AKT pathway inhibition might prevent or delay recurrence in patients with high-risk PIK3CA/AKT/PTEN-altered tumours. The scientific rationale for earlier-stage intervention is supported by the observation that PI3K/AKT pathway alterations are detectable at diagnosis and are not exclusively acquired resistance mechanisms.

Triple-negative breast cancer (TNBC) and HER2-positive disease also represent potential expansion contexts, given that PTEN loss and AKT activation are observed across breast cancer subtypes. The pan-AKT mechanism of capivasertib is subtype-agnostic at the molecular level, and the CAPItello programme’s expansion signals suggest AstraZeneca is evaluating whether the clinical benefit observed in HR+/HER2- disease can be replicated or extended in other biomarker-positive populations — a strategic direction consistent with the broader oncology industry trend toward histology-agnostic, biomarker-driven therapy, as tracked by PatSnap’s innovation intelligence platform.

IP and Innovation Signals in AKT Inhibition for Breast Cancer

The intellectual property landscape surrounding AKT inhibitors in breast cancer reflects the growing clinical and commercial interest in PI3K/AKT/PTEN pathway-targeted therapy. AstraZeneca’s patent portfolio around capivasertib (AZD5363) encompasses composition-of-matter claims on the compound itself, method-of-use claims covering its application in breast cancer and other solid tumours with defined genomic alterations, and combination claims covering its use with endocrine agents including fulvestrant.

The IP strategy around biomarker-selected oncology drugs is increasingly important for commercial exclusivity. Method-of-use patents that specify PIK3CA, AKT1, or PTEN alteration status as a patient selection criterion can extend effective market exclusivity beyond the base composition-of-matter patent, because they protect the specific clinical application that generates commercial value. This approach — sometimes called “stratified medicine patenting” — is well established in oncology and is visible across the AKT inhibitor class, as documented in patent analyses published by organisations including WIPO.

Competitive IP signals in the AKT inhibitor space include activity from other pharmaceutical developers pursuing AKT-targeted agents for breast cancer and other solid tumours. MK-2206 (Merck), ipatasertib (Roche/Genentech), and other pan-AKT or isoform-selective inhibitors have generated patent filings and clinical data in overlapping indications, creating a competitive IP environment that AstraZeneca’s CAPItello programme is designed to navigate through biomarker specificity and clinical differentiation. The PatSnap pharmaceutical intelligence platform enables systematic tracking of these competitive patent signals across the AKT inhibitor class.

Innovation signals beyond capivasertib itself include next-generation AKT inhibitor designs — including allosteric inhibitors that bind outside the ATP-binding site and may offer improved selectivity or resistance profiles — as well as combination IP covering AKT inhibitors paired with PARP inhibitors, immunotherapy agents, and antibody-drug conjugates. The breadth of this innovation activity reflects the recognition that AKT inhibition, while clinically validated by CAPItello-291, may require further optimisation or combination to achieve durable responses in the face of acquired resistance mechanisms.